[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 45 of about 45
1. Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler DH: Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Biol Blood Marrow Transplant; 2003 Mar;9(3):162-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
  • Reduced-intensity allogeneic hematopoietic stem cell transplantation (alloHSCT), which typically results in mixed chimerism initially after transplantation, has had limited efficacy in chemotherapy-refractory lymphomas.
  • We hypothesized that the rapid establishment of complete donor chimerism would potentiate a graft-versus-lymphoma effect.
  • Fifteen patients with chemotherapy-refractory lymphoma initially received induction with a conventional chemotherapy regimen (etoposide, prednisone, vincristine, cyclophosphamide, adriamycin, fludarabine [EPOCH-F]) to deplete host T cells and provide disease control prior to alloHSCT.
  • There were two therapy-related deaths.
  • The 1-year progression-free survival rate from time of study entry is 67% with only 1 relapse among 9 CRs.
  • These data demonstrate that a potent and durable graft-versus-lymphoma effect can occur against chemotherapy-refractory lymphomas and suggest that this effect may be associated with rapid, complete donor chimerism after reduced-intensity alloHSCT.
  • [MeSH-major] Graft Survival. Graft vs Tumor Effect. Hematopoietic Stem Cell Transplantation / methods. Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / toxicity. Drug Administration Schedule. Female. Graft vs Host Disease / prevention & control. Hematopoiesis. Humans. Male. Middle Aged. Remission Induction / methods. Salvage Therapy. Survival Analysis. Time Factors. Transplantation Chimera. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Society for Blood and Marrow Transplantation
  • (PMID = 12652466.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Horning SJ, Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, Long GD, Brown BW, Blume KG: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood; 2001 Jan 15;97(2):404-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial.
  • Advanced stage follicular small cleaved and mixed cell lymphoma is characterized by relapse from remission and survival ranging from 6 to 12 years.
  • Because young patients have the greatest compromise in longevity, the efficacy and toxicity of high-dose radiochemotherapy and bone marrow transplantation after conventional chemotherapy was evaluated in a prospective phase II clinical trial.
  • Thirty-seven patients in a minimal disease state after conventional chemotherapy received fractionated total body irradiation and high-dose etoposide and cyclophosphamide, followed by purged autologous bone marrow.
  • With a median follow-up of 6.5 years, the estimated 10-year survival after transplantation was 86%.
  • There was a single lymphoma death yielding a 10-year disease-specific survival of 97%.
  • High tumor burden at diagnosis and incomplete response to chemotherapy adversely influenced survival in the reference but not in the transplanted patients.
  • The estimated risk of death of 14% and relapse of 30% at 10 years in our transplanted follicular lymphoma patients, the majority of whom had high tumor burdens, compares favorably with our observations in appropriately matched reference patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation / mortality. Lymphoma, Follicular / therapy
  • [MeSH-minor] Actuarial Analysis. Adult. Cohort Studies. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / standards. Cyclophosphamide / toxicity. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual. Prednisone / administration & dosage. Prednisone / standards. Prednisone / toxicity. Prospective Studies. Radiotherapy, Adjuvant. Recurrence. Remission Induction. Survival Rate. Transplantation, Autologous / mortality. Vincristine / administration & dosage. Vincristine / standards. Vincristine / toxicity

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11154216.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 34233; United States / NCI NIH HHS / CA / CA 49605
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


3. Ferri C: Mixed cryoglobulinemia. Orphanet J Rare Dis; 2008;3:25
HIV InSite. treatment guidelines - Pneumocystosis and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed cryoglobulinemia.
  • Mixed cryoglobulinemia (MC), type II and type III, refers to the presence of circulating cryoprecipitable immune complexes in the serum and manifests clinically by a classical triad of purpura, weakness and arthralgias.
  • The prevalence of 'essential' MC is reported as approximately 1:100,000 (with a female-to-male ratio 3:1), but this term is now used to refer to a minority of MC patients only.
  • Circulating mixed cryoglobulins, low C4 levels and orthostatic skin purpura are the hallmarks of the disease.
  • Differential diagnoses include a wide range of systemic, infectious and neoplastic disorders, mainly autoimmune hepatitis, Sjögren's syndrome, polyarthritis, and B-cell lymphomas.
  • The first-line treatment of MC should focus on eradication of HCV by combined interferon-ribavirin treatment.
  • Pathogenetic treatments (immunosuppressors, corticosteroids, and/or plasmapheresis) should be tailored to each patient according to the progression and severity of the clinical manifestations.
  • Long-term monitoring is recommended in all MC patients to assure timely diagnosis and treatment of the life-threatening complications.
  • [MeSH-minor] Adult. Aged. Antiviral Agents / therapeutic use. Female. Hepatitis C / complications. Hepatitis C / drug therapy. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Cryoglobulinemia.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2002 Jan;55(1):4-13 [11825916.001]
  • [Cites] Arthritis Rheum. 2002 Mar;46(3):585-97 [11920393.001]
  • [Cites] Arthritis Rheum. 2002 Mar;46(3):741-7 [11920410.001]
  • [Cites] Ann Rheum Dis. 2002 Jun;61(6):554-8 [12006334.001]
  • [Cites] Ann Intern Med. 2002 May 21;136(10):747-57 [12020143.001]
  • [Cites] JAMA. 2002 Aug 14;288(6):698-9 [12169072.001]
  • [Cites] Ann Intern Med. 2002 Oct 1;137(7):571-80 [12353944.001]
  • [Cites] Clin Exp Rheumatol. 2002 Sep-Oct;20(5):693-6 [12412202.001]
  • [Cites] Reumatismo. 2002 Oct-Dec;54(4):316-23 [12563365.001]
  • [Cites] Blood. 2003 May 15;101(10):3818-26 [12506023.001]
  • [Cites] Blood. 2003 May 15;101(10):3827-34 [12560225.001]
  • [Cites] Ann Rheum Dis. 2003 Dec;62(12):1230-3 [14644867.001]
  • [Cites] Rheumatology (Oxford). 2004 Feb;43(2):238-40 [13130149.001]
  • [Cites] Clin Nephrol. 2004 Feb;61(2):144-50 [14989635.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4262-7 [14999097.001]
  • [Cites] Arthritis Res Ther. 2004;6(2):R137-41 [15059277.001]
  • [Cites] Semin Arthritis Rheum. 2004 Jun;33(6):355-74 [15190522.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2305-8 [15248231.001]
  • [Cites] QJM. 2004 Aug;97(8):499-506 [15256607.001]
  • [Cites] Ter Arkh. 2004;76(8):61-8 [15471400.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):745-52 [15471561.001]
  • [Cites] Am J Med. 1966 Jun;40(6):837-56 [4956871.001]
  • [Cites] Ann Intern Med. 1995 Oct 15;123(8):615-20 [7677303.001]
  • [Cites] Arthritis Rheum. 1995 Dec;38(12):1859-60 [8849361.001]
  • [Cites] Arthritis Rheum. 1996 May;39(5):767-72 [8639173.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2604-13 [8640712.001]
  • [Cites] Clin Exp Rheumatol. 1996 Mar-Apr;14(2):219-20 [8737733.001]
  • [Cites] J Rheumatol. 1996 Sep;23(9):1641-3 [8877939.001]
  • [Cites] Br J Rheumatol. 1996 Oct;35(10):978-82 [8883436.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4638-45 [8977256.001]
  • [Cites] Br J Rheumatol. 1997 Mar;36(3):360-5 [9133969.001]
  • [Cites] Clin Rev Allergy Immunol. 1997 Spring;15(1):97-119 [9209804.001]
  • [Cites] Springer Semin Immunopathol. 1997;19(1):99-110 [9266634.001]
  • [Cites] Arthritis Rheum. 1997 Nov;40(11):2007-15 [9365090.001]
  • [Cites] Clin Exp Rheumatol. 1997 Nov-Dec;15(6):655-8 [9444422.001]
  • [Cites] Clin Immunol Immunopathol. 1998 May;87(2):124-9 [9614926.001]
  • [Cites] Clin Exp Rheumatol. 1998 Jul-Aug;16(4):506 [9706438.001]
  • [Cites] Science. 1998 Oct 30;282(5390):938-41 [9794763.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1485-92 [9819446.001]
  • [Cites] J Hepatol. 1998 Dec;29(6):879-86 [9875633.001]
  • [Cites] Ann Intern Med. 1999 Feb 2;130(3):226-30 [10049201.001]
  • [Cites] Arch Pathol Lab Med. 1999 Feb;123(2):119-25 [10050784.001]
  • [Cites] JAMA. 1999 May 5;281(17):1588 [10235149.001]
  • [Cites] Nephrol Dial Transplant. 1999 Jun;14(6):1558-60 [10383026.001]
  • [Cites] Gastroenterol Clin Biol. 1999 Mar;23(3):403-6 [10384347.001]
  • [Cites] Am J Med. 1962 Jan;32:142-7 [14466769.001]
  • [Cites] Nephrol Dial Transplant. 2004 Dec;19(12):3054-61 [15494358.001]
  • [Cites] Rheumatology (Oxford). 2005 Jan;44(1):89-94 [15381790.001]
  • [Cites] J Rheumatol. 2005 Jan;32(1):143-9 [15630740.001]
  • [Cites] Arch Intern Med. 2005 Jan 10;165(1):101-5 [15642884.001]
  • [Cites] Autoimmun Rev. 2005 Jan;4(1):8-15 [15652773.001]
  • [Cites] J Hepatol. 2005 Mar;42(3):334-40 [15710215.001]
  • [Cites] Clin Exp Immunol. 1973 Dec;15(4):483-96 [4778718.001]
  • [Cites] Am J Med. 1974 Nov;57(5):775-88 [4216269.001]
  • [Cites] N Engl J Med. 1977 Jun 30;296(26):1501-4 [865530.001]
  • [Cites] Am J Med. 1979 May;66(5):748-56 [443251.001]
  • [Cites] Am J Med. 1980 Aug;69(2):287-308 [6996482.001]
  • [Cites] Acta Haematol. 1983;70(2):73-82 [6408882.001]
  • [Cites] Nephron. 1986;43(4):246-53 [3736735.001]
  • [Cites] Ric Clin Lab. 1986 Apr-Jun;16(2):281-8 [2947311.001]
  • [Cites] Acta Haematol. 1988;79(1):20-5 [3124457.001]
  • [Cites] Science. 1989 Apr 21;244(4902):359-62 [2523562.001]
  • [Cites] Am J Med. 1989 Nov;87(5):519-24 [2816967.001]
  • [Cites] J Infect Dis. 1990 Aug;162(2):569-70 [2115556.001]
  • [Cites] Clin Exp Rheumatol. 1990 May-Jun;8(3):271-81 [2379342.001]
  • [Cites] Lancet. 1991 Aug 3;338(8762):277-80 [1677111.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3142-7 [1742481.001]
  • [Cites] Clin Exp Rheumatol. 1991 Nov-Dec;9(6):621-4 [1662567.001]
  • [Cites] Ann Intern Med. 1992 Oct 1;117(7):573-7 [1326246.001]
  • [Cites] J Rheumatol. 1992 Jun;19(6):889-95 [1328632.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1490-5 [1383822.001]
  • [Cites] J Hepatol. 1992 Jul;15(3):382-6 [1332999.001]
  • [Cites] Blood. 1993 Mar 1;81(5):1132-6 [8382969.001]
  • [Cites] Arthritis Rheum. 1993 Oct;36(10):1341-9 [8216392.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3701-4 [8260706.001]
  • [Cites] Nephrol Dial Transplant. 1993;8(11):1193-8 [8302454.001]
  • [Cites] N Engl J Med. 1994 Mar 17;330(11):751-6 [8107741.001]
  • [Cites] Hepatology. 1994 Apr;19(4):841-8 [8138255.001]
  • [Cites] Gastroenterology. 1994 May;106(5):1291-300 [7513667.001]
  • [Cites] J Intern Med. 1994 Jul;236(1):31-6 [8021570.001]
  • [Cites] J Immunol Methods. 1994 Jul 12;173(1):63-75 [8034987.001]
  • [Cites] Br J Rheumatol. 1994 Aug;33(8):791-2 [8055216.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3047-53 [7949176.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):392-4 [7803287.001]
  • [Cites] QJM. 1995 Feb;88(2):115-26 [7704562.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1887-92 [7655017.001]
  • [Cites] Muscle Nerve. 2005 Mar;31(3):382-5 [15515001.001]
  • [Cites] J Rheumatol. 2005 Mar;32(3):484-8 [15742440.001]
  • [Cites] Medicine (Baltimore). 2005 Mar;84(2):81-9 [15758837.001]
  • [Cites] J Hepatol. 2005 Mar;42(3):315-22 [15791697.001]
  • [Cites] J Hepatol. 2005 May;42(5):632-8 [15826710.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1019-27 [16231354.001]
  • [Cites] Curr Opin Rheumatol. 2006 Jan;18(1):54-63 [16344620.001]
  • [Cites] J Infect. 2006 Apr;52(4):294-9 [16026843.001]
  • [Cites] Hepatology. 2006 May;43(5):1166-7; author reply 1167-8 [16628675.001]
  • [Cites] Autoimmun Rev. 2006 Aug;5(7):493-8 [16920576.001]
  • [Cites] Arthritis Rheum. 2006 Nov;54(11):3696-706 [17075881.001]
  • [Cites] Dig Liver Dis. 2007 Jan;39(1):2-17 [16884964.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1107:308-18 [17804559.001]
  • [Cites] Curr Opin Rheumatol. 2007 Nov;19(6):619-25 [17917544.001]
  • [Cites] Dig Liver Dis. 2007 Sep;39 Suppl 1:S13-21 [17936215.001]
  • [Cites] Dig Liver Dis. 2007 Sep;39 Suppl 1:S61-4 [17936226.001]
  • [Cites] Rheumatology (Oxford). 2007 Nov;46(11):1657-61 [17893101.001]
  • [Cites] Autoimmun Rev. 2007 Dec;7(2):114-20 [18035320.001]
  • [Cites] Ann Rheum Dis. 2008 Mar;67(3):283-7 [17644544.001]
  • [Cites] Arthritis Rheum. 2008 Feb;58(2):604-11 [18240235.001]
  • [Cites] J Virol. 2008 Apr;82(7):3466-79 [18216094.001]
  • [Cites] Clin Exp Rheumatol. 2008 Jan-Feb;26(1 Suppl 48):S39-47 [18570753.001]
  • [Cites] Arthritis Rheum. 1999 Dec;42(12):2507-16 [10615995.001]
  • [Cites] Ann Rheum Dis. 2000 Jan;59(1):20-5 [10627422.001]
  • [Cites] Ann Rheum Dis. 2000 Jun;59(6):490-2 [10885976.001]
  • [Cites] Curr Opin Rheumatol. 2000 Jul;12(4):295-9 [10910182.001]
  • [Cites] Semin Liver Dis. 2000;20(2):143-57 [10946420.001]
  • [Cites] J Rheumatol. 2000 Sep;27(9):2172-8 [10990230.001]
  • [Cites] Ann Intern Med. 2000 Oct 17;133(8):592-9 [11033586.001]
  • [Cites] Medicine (Baltimore). 2001 Jan;80(1):1-8 [11204499.001]
  • (PMID = 18796155.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 128
  • [Other-IDs] NLM/ PMC2569912
  •  go-up   go-down


Advertisement
4. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X: Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis; 2007 Mar;66(3):351-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
  • OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers.
  • RTX was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).
  • Efficacy of treatment was observed in 4 of 5 patients with lymphomas and in 9 of 11 patients with systemic involvement.
  • RTX induced decreased rheumatoid factor, gamma-globulin and beta2-microglobulin levels, and the level of B cell activating factor of the tumour necrosis factor family (BAFF) increased concomitantly with B cell depletion.
  • Except for BAFF, the level of which increases, serum B cell biomarker levels decrease after taking RTX.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antirheumatic Agents / therapeutic use. B-Lymphocytes / drug effects. Sjogren's Syndrome / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Biomarkers / blood. Drug Administration Schedule. Drug Therapy, Combination. Female. Glucocorticoids / administration & dosage. Humans. Lymphoma, B-Cell / drug therapy. Middle Aged. Retrospective Studies. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2001 Jul;44(7):1717-8 [11465726.001]
  • [Cites] Clin Rheumatol. 2006 Nov;25(6):891-4 [16283417.001]
  • [Cites] Clin Nucl Med. 2002 Feb;27(2):142-3 [11786752.001]
  • [Cites] Ann Rheum Dis. 2002 Jun;61(6):554-8 [12006334.001]
  • [Cites] Am J Hematol. 2002 Aug;70(4):329 [12214584.001]
  • [Cites] Blood. 2003 May 15;101(10):3818-26 [12506023.001]
  • [Cites] Blood. 2003 May 15;101(10):3827-34 [12560225.001]
  • [Cites] Arthritis Rheum. 2003 Jun 15;49(3):394-8 [12794796.001]
  • [Cites] Curr Opin Rheumatol. 2003 Sep;15(5):563-70 [12960481.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1792 [14630688.001]
  • [Cites] J Pathol. 2004 Apr;202(4):496-502 [15095277.001]
  • [Cites] N Engl J Med. 2004 Jun 17;350(25):2572-81 [15201414.001]
  • [Cites] J Immunol Methods. 2004 Jun;289(1-2):97-109 [15251416.001]
  • [Cites] Rheumatology (Oxford). 2004 Aug;43(8):1050-3 [15187246.001]
  • [Cites] Rheumatology (Oxford). 2004 Oct;43(10):1309-10 [15448217.001]
  • [Cites] Lupus. 2004;13(12):969-71 [15645755.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):406 [15637037.001]
  • [Cites] Ann Rheum Dis. 2005 Jun;64(6):913-20 [15550531.001]
  • [Cites] Ann Rheum Dis. 2005 Jun;64(6):958-60 [15576414.001]
  • [Cites] Ann Rheum Dis. 2005 Jul;64(7):1050-5 [15640273.001]
  • [Cites] Ann Rheum Dis. 2005 Jul;64(7):1087-8 [15958765.001]
  • [Cites] Curr Opin Rheumatol. 2005 Sep;17(5):550-7 [16093832.001]
  • [Cites] Arthritis Rheum. 2005 Sep;52(9):2740-50 [16142737.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Arthritis Rheum. 2006 Mar;54(3):723-32 [16508933.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2770-5 [16477017.001]
  • [Cites] Ann Rheum Dis. 2006 Jun;65(6):796-803 [16284097.001]
  • [Cites] Ann Rheum Dis. 2006 Aug;65(8):1033-7 [16322082.001]
  • [Cites] J Immunol. 2001 Oct 1;167(7):3610-8 [11564773.001]
  • (PMID = 16950808.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 0 / Biomarkers; 0 / Glucocorticoids; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC1856024
  •  go-up   go-down


5. Widder S, Pasieka JL: Primary thyroid lymphomas. Curr Treat Options Oncol; 2004 Aug;5(4):307-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary thyroid lymphomas.
  • Primary thyroid lymphoma is a rare disease that continues to produce diagnostic and therapeutic dilemmas.
  • There was great difficulty in distinguishing thyroid lymphoma from anaplastic thyroid carcinoma but, because of new immunocytochemical staining techniques and increased cytopathologic knowledge, our ability to diagnose thyroid lymphoma has improved drastically over the past decade.
  • Surgery that was once the mainstay of treatment for this disease, now plays a minimal role.
  • Current treatment regimens for primary thyroid lymphoma consist of chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) and external beam radiation.
  • The overall and distant relapse rates have been shown to be significantly lower in those patients receiving combined modality therapy compared to chemotherapy or radiation alone.
  • Although the role of surgery has changed over time, it continues to play an important role, especially in confirming diagnoses through open biopsies, potentially providing local control in the more indolent subtypes, and may play a role in the palliation of symptoms for large obstructive lymphomas.
  • The evolving classification of extranodal lymphomas has brought about a better understanding of the biologic behavior of these tumors.
  • Most thyroid lymphomas are B-cell origin, with six different histologic subtypes, but there appears to be two distinct clinical and prognostic groupings of these rare tumors.
  • The more indolent lymphomas are the subgroup of mucosa-associated lymphoid tissue (MALT) lymphomas comprising approximately 6% to 27% of thyroid lymphomas.
  • This subgroup, when localized to the thyroid (stage IE), responds well to total thyroidectomy or radiation with a complete response rate of more than 90%, leading some authors to recommend surgery as primary therapy in the treatment of localized MALT lymphomas.
  • Therefore, surgery as a primary treatment for thyroid lymphomas would only be recommended under ideal conditions, such as MALT subtype stage IE only, and completely resectable with minimal morbidity.
  • The more common subtype, comprising up to 70% of cases, is diffuse large B-cell lymphoma.
  • Up to 40% of all diffuse large cell lymphomas appear to have undergone transformation from a MALT lymphoma, but they behave in a similar fashion to diffuse large cell lymphomas.
  • Treatment for these tumors should include chemotherapy and radiation.
  • Surgery is rarely beneficial in diffuse large cell lymphoma and the mixed large cell subtypes because the disease is generally disseminated and surgical excision of all disease is not possible or associated with increased morbidity.
  • However, there may be a role for palliative surgical debulking to alleviate obstructive symptoms while the patient is undergoing standard chemotherapy and radiation.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Thyroid Neoplasms / pathology. Thyroid Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Clinical Trials as Topic. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Radiotherapy, High-Energy / methods. Risk Assessment. Survival Analysis. Thyroidectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Otol Rhinol Laryngol. 1998 Feb;107(2):149-54 [9486910.001]
  • [Cites] Cytopathology. 2001 Aug;12(4):257-63 [11488875.001]
  • [Cites] Eur J Surg. 2002;168(10):572-4 [12666700.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Apr;84(4):1206-9 [10199754.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):338-41 [11352307.001]
  • [Cites] N Engl J Med. 1985 Mar 7;312(10):601-4 [3838363.001]
  • [Cites] Int J Mol Med. 2002 Jul;10(1):113-7 [12060861.001]
  • [Cites] Thyroid. 1999 Dec;9(12):1273-80 [10646671.001]
  • [Cites] Br J Surg. 1980 Jul;67(7):475-7 [7417748.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):316-23 [10375088.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Br J Surg. 1976 Apr;63(4):253-8 [1276656.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1807-12 [2428787.001]
  • [Cites] Curr Treat Options Oncol. 2003 Aug;4(4):269-79 [12943607.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):298-302 [11923138.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):105-11 [11788631.001]
  • [Cites] Cancer. 1999 Dec 25;87(6):325-45 [10603186.001]
  • [Cites] Cancer. 1994 Jan 1;73(1):200-6 [8275426.001]
  • [Cites] Histopathology. 1996 Jan;28(1):25-32 [8838117.001]
  • [Cites] Neth J Med. 1998 Feb;52(2):75-8 [9557530.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):623-39 [10800981.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2741-5 [12842999.001]
  • [Cites] World J Surg. 2000 Aug;24(8):966-70 [10865042.001]
  • [Cites] J Laryngol Otol. 2001 Nov;115(11):935-7 [11779317.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):907-11 [12417514.001]
  • [Cites] J Clin Pathol. 1998 Mar;51(3):189-96 [9659258.001]
  • [Cites] Radiology. 1989 May;171(2):439-43 [2649921.001]
  • (PMID = 15233907.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


6. Adelusola KA, Titiloye NA, Rotimi O, Durosinmi M: Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians. Afr Health Sci; 2009 Sep;9(3):174-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians.
  • BACKGROUND: The burden of lymphomas on the health care system in Nigeria is enormous.
  • The rest were non-Hodgkin's lymphoma (2 diffuse large B-cell and 1 null cell ALCL).
  • All were cases of classical HL with 60% being of the mixed cellularity (MC) subtype.
  • Three patients had chemotherapy.
  • CONCLUSION: Mixed cellularity is the most common subtype and is the only subtype associated with EBV positivity in this study.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pathol. 2000 Oct;53(5):262-9 [11091850.001]
  • [Cites] Histopathology. 2008 May;52(6):775-7 [18439160.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):566-73 [12808062.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Afr J Med Med Sci. 1992 Oct;21(1):79-83 [1288248.001]
  • [Cites] Leukemia. 1994 Apr;8 Suppl 1:S77-82 [8152310.001]
  • [Cites] Br J Haematol. 2005 Jun;129(5):615-7 [15916683.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):55-62 [16007870.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):747-55 [16084943.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):395-405 [11523539.001]
  • (PMID = 20589147.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC2887026
  • [Keywords] NOTNLM ; Epstein-Barr virus / Hodgkin's lymphoma in Nigerians
  •  go-up   go-down


7. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R: Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res; 2002 Oct 15;62(20):5845-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
  • B-cell lymphomas express tumor-specific immunoglobulin, the variable regions of which [idiotype (Id)] can serve as a target for active immunotherapy.
  • Promising results have been obtained in clinical studies of Id vaccination using Id proteins.However, Id protein is laborious and time-consuming to produce.
  • DNA coding for lymphoma Id can provide protective immunity in murine models.
  • In the present study, we performed a Phase I/II clinical trial to study the safety and immunogenicity of naked DNA Id vaccines in 12 patients with follicular B-cell lymphoma.
  • Patients in remission after chemotherapy received three monthly i.m. injections of the DNA in three dose escalation cohorts of four patients each (200, 600, and 1800 micro g).
  • After vaccination, 7 of 12 patients mounted either humoral (n = 4) or T-cell-proliferative (n = 4) responses to the MsIg component of the vaccine.
  • In one patient, a T-cell response specific to autologous Id was also measured.
  • ); 9 of 12 patients had humoral (n = 6) and/or T-cell (n = 4) responses to MsIg.
  • Six of 12 patients exhibited humoral and/or T-cell anti-Id responses; yet, these were cross-reactive with Id proteins from other patient's tumors.
  • Subsequently, a third series of vaccinations was carried out using 500 micro g of human granulocyte-macrophage colony-stimulating factor DNA mixed with 1800 micro g of Id DNA.
  • The proportion of patients responding to MsIg remained essentially unchanged (8 of 12), although humoral or T-cell responses were boosted in some cases.
  • [MeSH-major] Cancer Vaccines / immunology. Immunoglobulin Idiotypes / immunology. Immunotherapy, Active / methods. Lymphoma, B-Cell / immunology. Vaccines, DNA / immunology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Immunologic. Follow-Up Studies. Granulocyte-Macrophage Colony-Stimulating Factor / genetics. Granulocyte-Macrophage Colony-Stimulating Factor / immunology. Humans. Plasmids / genetics. Prednisone / administration & dosage. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / immunology. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12384547.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA33399; United States / NHLBI NIH HHS / HL / HL57443; United States / NCRR NIH HHS / RR / RR-00070-CAP
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Immunoglobulin Idiotypes; 0 / Recombinant Fusion Proteins; 0 / Vaccines, DNA; 5J49Q6B70F / Vincristine; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


8. Castagna L, Bertuzzi A, Nozza A, Siracusano L, Balzarotti M, Magagnoli M, Sarina B, Timofeeva I, Sinnone M, Grimoldi MG, Farè M, Santoro A: Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas. Bone Marrow Transplant; 2002 Aug;30(4):207-14
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
  • The aim of this pilot study was to exploit the graft-versus-tumor potential of allogeneic transplants while improving safety of the procedure.
  • Twelve patients with advanced hematological malignancies and solid tumors underwent a low intensity conditioning regimen (fludarabine and cyclophosphamide) followed by an allogeneic peripheral blood stem cell transplantation.
  • The median time to achieve an absolute neutrophil count of more than 0.5 x 10(9)/l and an untransfused platelet count of more than 20 x 10(9)/l was 15 and 14 days, respectively.
  • One patient showed a mixed chimerism at day +37 when he died from progressive disease.
  • Our study confirms that a low intensity conditioning regimen for allogeneic stem cell transplantation is feasible and effective in heavily pretreated patients.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / administration & dosage. Immunosuppressive Agents / administration & dosage. Lymphoma / therapy. Neoplasms / therapy. Peripheral Blood Stem Cell Transplantation / methods. Transplantation Conditioning / methods. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / toxicity. Cyclophosphamide / administration & dosage. Female. Graft Survival. Graft vs Host Disease / drug therapy. Hematopoietic Stem Cell Mobilization / methods. Humans. Male. Middle Aged. Pilot Projects. Recombinant Proteins. Survival Analysis. Transplantation, Homologous / adverse effects. Transplantation, Homologous / methods

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12203136.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


9. Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, Hurd DD, Henderson ES, Sartiano GP, Johnson JL, Holland JF, Gottlieb AJ: Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol; 2003 Jan 1;21(1):5-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B.
  • PURPOSE: The array of options for the initial management of follicular small cleaved lymphoma (FSCL) and follicular mixed lymphoma (FML) ranges from little or no therapy to the use of intensive combinations of drugs.
  • The Cancer and Leukemia Group B (CALGB) compared two contrasting approaches: a single agent, and combination chemotherapy capable of curing diffuse aggressive lymphomas.
  • Treatment was continued in responders for 2 years beyond maximal response.
  • At 10 years with either cyclophosphamide or CHOP-B, respectively, overall time to failure (25% failure free v 33%; P =.107) and survival (44% alive v 46%; P =.79) were similar by treatment.
  • Acute toxic effects were more common with combination chemotherapy.
  • Second malignancies, which might be attributed to treatment, were seen with both approaches.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Lymphoma, Follicular / drug therapy. Prednisone / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2003 Jan 1;21(1):1-2 [12506161.001]
  • (PMID = 12506163.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP-B protocol
  •  go-up   go-down


10. Jezersek Novaković B, Vovk M, Juznic Setina T: A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003. Ann Hematol; 2006 Dec;85(12):849-56
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003.
  • Primary gastric lymphomas are the most common extranodal non-Hodgkin's lymphomas and are divided into indolent (low grade) and aggressive (high grade) types.
  • They are mainly the disease of middle age, with a male predominance reported by most of the studies.
  • For several years, surgery played a central role in diagnosis, staging, and treatment of this entity, yet recently there has been a move away from a surgical approach to conservative treatment.
  • To determine the role of surgery as the initial treatment modality, we performed this retrospective single-center research on 245 patients with primary gastric lymphoma who were treated according to our protocol between 1990 and 2003.
  • The patients' characteristics, distribution of histological types, treatment results, and disease-specific survival were followed.
  • According to the histology, 59.2% had diffuse large B-cell lymphoma (DLCL), 26.1% MALT lymphoma, 9.8% mixed lymphoma (indolent and aggressive at the same time), while other types were infrequent.
  • In total, 161 patients (65.7%) were treated with surgical resection as the initial treatment, which was then followed or not by additional therapy (chemotherapy, chemotherapy and radiotherapy, radiotherapy) depending on the histological type of lymphoma and the extent of residual disease after surgery.
  • In 84 patients (34.3%), the treatment approach was conservative.
  • The selection of treatment (chemotherapy, chemotherapy and radiotherapy, radiotherapy or Helicobacter pylori eradication only) was based on the histological type of lymphoma, considering also the patients' physical condition.
  • However, the results were biased, as the patients who were treated conservatively were either in a worse performance status or presented with a more extensive disease.
  • Similarly, in the DLCL type the disease-specific survival was better in the surgically treated group (97.2%) than in the conservatively treated patients (89.2%).
  • The difference was barely significant (p=0.046) and again the results have to be considered with caution due to the selection of patients in a worse performance status or with a more extensive disease for conservative treatment.
  • In the MALT lymphoma and mixed lymphoma types, there were no differences in the disease-specific survival between both treatment groups.
  • Regarding the statement that for conservative treatment patients were selected who were unsuitable for the resection on account of concomitant diseases or due to the fact that the process was inoperable, we believe that the conservative approach gives comparable outcomes to the approach including initial surgery.
  • The existing evidence thus no longer justifies surgery as the standard initial treatment and preference should be given to conservative treatment approaches.
  • [MeSH-major] Lymphoma / mortality. Lymphoma / surgery. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Helicobacter Infections / epidemiology. Helicobacter pylori / pathogenicity. Humans. Lymphoma, B-Cell, Marginal Zone / mortality. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / surgery. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / surgery. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944146.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K, Fournel-Fleury C: Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Vet J; 2004 Mar;167(2):158-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy.
  • The aim of this study was to determine the response of different morphological subtypes of canine lymphoma to a standardized therapeutic protocol.
  • Diagnosis of lymphoma was based on cytohistological analysis and immunophenotyping with antibodies against CD3 and CD79a of an enlarged lymph node or an extranodal mass.
  • Fifty-seven cases were classified according to the updated Kiel classification adapted to the canine species, into 24 B-cell lymphomas (20 centroblastic polymorphic and four Burkitt-type subtypes), and 33 T-cell lymphomas (10 pleomorphic mixed, 10 lymphoblastic, eight unclassifiable high grade plasmacytoid, and five small clear-cell subtypes).
  • First remission duration and overall survival time were evaluated.
  • Although the T-cell phenotype was associated, on the whole, with a poor prognosis, as previously reported in veterinary and human medicine, the study showed significant prognostic differences between the B- and the T-cell subtypes of canine lymphoma and suggests that clinico-morphological characterization of the disease is justified in dogs, as in humans.
  • [MeSH-major] Dog Diseases / classification. Dog Diseases / epidemiology. Lymphoma / veterinary
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dogs. Female. France / epidemiology. Immunophenotyping / veterinary. Male. Prognosis. Records as Topic / veterinary. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vet J. 2004 Mar;167(2):125-6 [14975385.001]
  • (PMID = 14975390.001).
  • [ISSN] 1090-0233
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Bandyopadhyay SK, Dutta S, Dutta A: Panniculitis-like T-cell lymphoma with fatal termination. J Indian Med Assoc; 2005 Oct;103(10):551-2
Genetic Alliance. consumer health - Panniculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Panniculitis-like T-cell lymphoma with fatal termination.
  • Three months later, the patient presented with carvical lymphadenopathy and compressive thoracic myelopathy and a diagnosis of diffuse mixed- cell lymphoma was established.
  • Immunohistochemical study of subcutaneous lesions confirmed their T-cell origin.
  • Chemotherapy was started but patient succumbed to his disease.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Panniculitis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498764.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


13. Lo HC, Yu DS, Lee CT, Chen A, Chang SY, Sun GH: Primary B cell lymphoma of the penis: successful treatment with organ preservation. Arch Androl; 2003 Nov-Dec;49(6):467-70
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary B cell lymphoma of the penis: successful treatment with organ preservation.
  • Malignant lymphoma uncommonly manifests in the genitourinary tract.
  • Primary penile lymphoma is extremely rare.
  • A 77-year-old male presented with primary malignant B-cell lymphoma of the penis with the chief complaint of a painless and itching nodule on the penile glans for more than 2 months.
  • The pathologic examination with immunohistochemical stain of penile biopsy revealed malignant B cell lymphoma, mixed cellular type.
  • The physical examination and the computed tomography scan of chest, abdomen, and pelvis showed no evidence of superficial, thoracic, abdominal, or pelvic lymphadenopathy.
  • This case was treated with local excision and systemic chemotherapy with good cosmetic and functional results.
  • There was absence of recurrence 16 months after therapy.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Penile Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Humans. Immunohistochemistry. Male. Prednisolone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14555331.001).
  • [ISSN] 0148-5016
  • [Journal-full-title] Archives of andrology
  • [ISO-abbreviation] Arch. Androl.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


14. Ang MK, Hee SW, Quek R, Yap SP, Loong S, Tan L, Tao M, Lim ST: Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis. Ann Hematol; 2009 May;88(5):417-24
Genetic Alliance. consumer health - Gastric Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
  • Gastric mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B cell lymphoma (DLBCL) show a spectrum of disease characterized by varying proportions of low-grade and high-grade components.
  • While the natural history and optimum treatment for low-grade gastric MALT lymphoma and DLBCL is well established, the prognosis and optimal treatment of patients with both low- and high-grade components is not well established.
  • The purpose of our study was to evaluate the clinical characteristics, survival outcomes, and prognostic factors of patients with gastric MALT lymphoma and gastric DLBCL.
  • A retrospective review of patients with gastric MALT lymphoma, gastric DLBCL, or MALT lymphoma with a high-grade component treated at our centers from 1994 to 2006 was performed.
  • Patients were divided into three categories: "pure MALT lymphoma," "MALT lymphoma with high-grade component" (mixed), and "pure DLBCL."
  • Seventy-six patients were included in our study-26 with pure MALT, 22 with MALT with high-grade component ("mixed"), and 28 with pure DLBCL.
  • Pure MALT lymphoma and mixed lymphoma patients had similar clinical characteristics, whereas pure DLBCL patients had less favorable disease characteristics with significantly poorer performance status, higher number of extranodal sites of disease, higher stage, and larger proportion of bone marrow involvement and international prognostic index (IPI) scores compared with mixed lymphoma.
  • The majority of mixed lymphoma (72.7%) and DLBCL patients (71.4%) were treated with chemotherapy.
  • Of patients receiving chemotherapy, a higher proportion of mixed lymphoma and DLBCL patients received anthracycline-based combination chemotherapy regimens compared with MALT lymphoma (73% vs 71% vs 8%) whereas the proportion of mixed lymphoma and DLBCL patients was similar (p = 0.919).
  • The 5-year overall survival was 78% for MALT lymphoma, 84% for mixed lymphoma, and 45% for DLBCL.
  • On multivariate analysis, DLBCL histology remained significantly prognostic for inferior survival, independent of chemotherapy regimen (hazard ratio (HR) 6.66, 95% confidence interval (CI) 2.01-21.41, p = 0.001).
  • Mixed histology was not prognostic for inferior survival (HR 1.13, 95% CI 0.28-4.54, p = 0.868).
  • Other factors prognostic for inferior survival were serum albumin <37 g/L (HR 3.22, 95% CI 1.11-13.22, p = 0.034) and treatment with non-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy (HR 4.89, 95% CI 1.67-14.36, p = 0.004).
  • In conclusion, the clinical characteristics of mixed histology MALT lymphoma are similar to low-grade MALT lymphoma and significantly different from pure DLBCL.
  • The prognosis of mixed histology MALT lymphoma is significantly better than pure DLBCL, independent of IPI and chemotherapy regimen, and pure DLBCL histology is independently prognostic of inferior survival outcome.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers / blood. Bone Marrow Neoplasms. Follow-Up Studies. Histological Techniques. Humans. L-Lactate Dehydrogenase / analysis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Serum Albumin / analysis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18777110.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Serum Albumin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


15. Green LD, Mack L, Pasieka JL: Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies. J Surg Oncol; 2006 Dec 15;94(8):725-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies.
  • BACKGROUND: To review the current literature on the treatment of anaplastic thyroid cancer (ATC) and thyroid lymphoma (TL).
  • Multimodality therapy consisting of both radiotherapy (RT) and chemotherapy is essential in obtaining local/regional control.
  • The role of surgery in the treatment of ATC continues to evolve, presently it should be reserved for patients who have shown an initial response to multimodality therapy and in patients in whom a complete macroscopic resection can be achieved with minimal morbidity.
  • The successful treatment of TL currently lies in accurately diagnosing the histological subtype.
  • Both large B-cell and mixed lymphomas are best treated with multimodality therapy consisting of CHOP combined with hyper-fractioned RT.
  • MALT lymphomas with there more indolent course may be amenable to single modality RT or total thyroidectomy if diagnosed at an early stage IE.
  • DISCUSSION: Although both ATC and TL are rare, it is important for surgeons to be aware of the need for multimodality therapy when treating these patients and to understand the limited role surgery plays in diagnosis and treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma. Lymphoma. Thyroid Neoplasms. Thyroidectomy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell, Marginal Zone / drug therapy. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Vincristine / administration & dosage


16. Hartmann BL, Winder T, Sandholzer M, Gasser K, Jäger I, Lang AH, Längle M, Hartmann G, Bartenstein C, Luger C: JC papovavirus leukencephalopathy in a patient with B-CLL receiving long-term chemotherapy in combination with an anti-CD20-antibody. J Clin Oncol; 2009 May 20;27(15_suppl):e18007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JC papovavirus leukencephalopathy in a patient with B-CLL receiving long-term chemotherapy in combination with an anti-CD20-antibody.
  • It is almost exclusively described in profound immunocompromised patients developed as a primary infection or by reactivation of the virus after a latent infection.
  • METHODS: Our patient was a 64-year-old woman with B-CLL diagnosed in 2000 in state B of Binet treated with 12 cycles of fludarabin until July 2007 in a B-cell and lymphoma-reducing manner.
  • RESULTS: In a CT scan mixed response was observed with progressive disease infradiafragmatic and regression supradiafragmatic.
  • Corticosteroids could stop B-symptoms and leads to a distinct shrinkage of the lymphomas within 2 weeks.
  • CONCLUSIONS: Antibody deficiency syndrome corresponding to CLL under treatment with chemotherapy and rituximab lead to a severe immunosuppression enabling unusual viral infections such as PML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963992.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Azim HA, Malek RA, Santoro L, Gandini S, Bociek RG, Azim HA Jr: High-dose intense doxorubicin-based regimens in aggressive non-Hodgkin's lymphoma: A systematic overview. J Clin Oncol; 2009 May 20;27(15_suppl):e19528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose intense doxorubicin-based regimens in aggressive non-Hodgkin's lymphoma: A systematic overview.
  • : e19528 Background: Aggressive non-Hodgkin's lymphoma represents around 60% of lymphomas in the Western world and even more in Egypt.
  • CHOP has been long been recognized as the standard chemotherapy regimen in this disease.
  • The addition of rituximab (R) to CHOP in the treatment of B-cell subtypes has resulted in a significant improvement in all treatment endpoints.
  • Thus CHOP is still offered to these patients as well as those with T-cell subtypes.
  • Hence we conducted a metaanalysis on chemotherapy regimens incorporating higher DI doxorubicin and compare them to CHOP in terms of complete response (CR) rate, event free survival (EFS) and overall survival (OAS).
  • METHODS: A MEDLINE and COCHRANE library search was performed using the search terms 'CHOP', 'lymphoma' and 'randomized trials'.
  • Eligible trials were randomized trials, having CHOP as a control arm and any chemotherapy regimen administering doxorubicin at a higher DI than that of CHOP (16mg/m2/week) as the investigational arm.
  • Pooling of data was performed using the mixed effect model.
  • Confidence intervals were estimated according to the method developed by Parmar.
  • CONCLUSIONS: High DI doxorubicin-based regimens are associated with a better OAS compared to CHOP.
  • Such approach should be considered in patients with aggressive B-cell lymphomas not offered R as well as those with T-cell lymphomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960914.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas AG: Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford); 2004 Aug;43(8):1050-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
  • OBJECTIVE: To determine the safety and therapeutic response of a regimen consisting of cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) plus rituximab in patients with Sjögren's syndrome (SS) and aggressive non-Hodgkin's lymphoma (NHL).
  • Three out of four patients also had mixed cryoglobulinaemia (MC) of type II.
  • RESULTS: Complete remission of lymphoma was achieved in all four patients.
  • The lymphoma patients remained in remission for a period of 23, 15, 12 and 10 months respectively, while certain signs and symptoms of MC type II (purpura, peripheral neuropathy and arthralgias) significantly improved with treatment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Lymphoma, B-Cell / drug therapy. Prednisone / therapeutic use. Sjogren's Syndrome / complications. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, CD / analysis. B-Lymphocytes / immunology. Cryoglobulinemia / etiology. Drug Therapy, Combination. Humans. Middle Aged. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15187246.001).
  • [ISSN] 1462-0324
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Chen KN, Xu SF, Gu ZD, Zhang WM, Pan H, Su WZ, Li JY, Xu GW: Surgical treatment of complex malignant anterior mediastinal tumors invading the superior vena cava. World J Surg; 2006 Feb;30(2):162-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of complex malignant anterior mediastinal tumors invading the superior vena cava.
  • Determining the appropriate surgery-based treatment for complicated anterior mediastinal malignancies (CAMM), especially those invading the superior vena cava (SVC) and its branches, remains a challenge for general thoracic surgeons.
  • In this report, we summarize our experience and lessons regarding this issue in order to discuss a reasonable strategy for diagnosis and treatment of CAMM.
  • Thymic carcinoma, teratoma, embryonal carcinoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and mixed teratoma with thymoma were diagnosed in 1 patient each.
  • Four of the patients underwent perioperative chemotherapy.
  • CAMM should be pathologically identified before initial treatment.
  • A good outcome for patients with CAMM is possible if a suitable strategy combining accurate diagnosis and appropriate treatment, especially surgical resection, is established.
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Angiography. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / mortality. Preoperative Care. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis. Thymectomy / methods. Thymoma / drug therapy. Thymoma / mortality. Thymoma / pathology. Thymoma / surgery. Thymus Neoplasms / drug therapy. Thymus Neoplasms / mortality. Thymus Neoplasms / pathology. Thymus Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1988 Nov;6(11):1722-7 [3183702.001]
  • [Cites] J Surg Oncol. 1999 Feb;70(2):95-9 [10084651.001]
  • [Cites] Semin Diagn Pathol. 1991 Feb;8(1):2-13 [2047614.001]
  • [Cites] World J Surg. 2001 Feb;25(2):204-9 [11338023.001]
  • [Cites] Ann Thorac Surg. 1996 Feb;61(2):521-4 [8572759.001]
  • [Cites] J Pediatr Surg. 2001 Jan;36(1):18-24 [11150432.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2000 Oct;12(4):268-77 [11154722.001]
  • [Cites] Radiographics. 2000 Jan-Feb;20(1):67-81 [10682772.001]
  • [Cites] Minerva Cardioangiol. 2000 Mar;48(3):79-87 [10838837.001]
  • [Cites] AJR Am J Roentgenol. 1978 Aug;131(2):239-42 [209680.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2000 Oct;12(4):278-89 [11154723.001]
  • [Cites] Ann Thorac Surg. 1991 Mar;51(3):378-84; discussion 385-6 [1998414.001]
  • [Cites] J Thorac Cardiovasc Surg. 1984 Jan;87(1):43-7 [6690858.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 6;85(1):25-31 [8416252.001]
  • (PMID = 16425072.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Mazzaro C, Tirelli U, Pozzato G: Hepatitis C virus and non-Hodgkin's lymphoma 10 years later. Dig Liver Dis; 2005 Apr;37(4):219-26
Genetic Alliance. consumer health - Hepatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C virus and non-Hodgkin's lymphoma 10 years later.
  • Hepatitis C virus is associated with chronic liver disease as well as with lymphoproliferative disorders such as mixed cryoglobulinemia and, likely, non-Hodgkin's lymphomas.
  • The association between hepatitis C virus infection and B-cell lymphoma is controversial since it shows a strong regional variation.
  • In fact, the prevalence of hepatitis C virus infection in non-Hodgkin's lymphoma shows a prevalence ranging between 7.4 and 37.0%.
  • However, the intimate pathogenetic mechanism involved in hepatitis C virus-associated lymphomas remains considerably unknown.
  • It is reasonable to assume that several different pathogenetic mechanisms operate in the wide spectrum of hepatitis C virus-related lymphoproliferative disorders, which include the intermediate to high-grade lymphoma, and the more common indolent, low-grade lymphoma, preceded by long standing symptomatic mixed cryoglobulinemia Type II.
  • In this review, the etiopathogenetic role of hepatitis C virus in non-Hodgkin's lymphoma is discussed on the basis of molecular, clinical and epidemiological considerations.
  • The management of hepatitis C virus-associated non-Hodgkin's lymphoma is similar to that of conventional lymphoma, although viral reactivation or the underlying chronic liver disease can complicate chemotherapy.
  • Whether to treat low-grade hepatitis C virus-related lymphomas with anti-viral therapy is still debatable, but encouraging data emerge from some recent studies.
  • [MeSH-major] Hepacivirus. Hepatitis C, Chronic / complications. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] B-Lymphocytes / pathology. Cell Proliferation. Cryoglobulinemia / etiology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788203.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 119
  •  go-up   go-down


23. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL: Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol; 2000 May;24(5):623-39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases.
  • We report a retrospective clinicopathologic study of 108 primary thyroid gland lymphomas (PTLs), classified using the REAL and proposed WHO classification schemes.
  • All patients presented with a thyroid mass.
  • The PTLs were classified as marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) or MZBL (n = 30), diffuse large B-cell lymphoma (DLBCL) with MZBL (n = 36), DLBCL without MZBL (n = 41), and follicle center lymphoma (FCL; n = 1).
  • Excluding the FCL, features of lymphomas of MALT-type were identified in all groups, despite a follicular architecture in 23% of cases.
  • Lymphocytic thyroiditis (LT) was identified in 94%.
  • Ninety-one percent of patients presented with stage IE or IIE disease, whereas 69% had perithyroidal soft tissue infiltration.
  • All patients were treated with surgical excision followed by adjuvant therapy (76%): chemotherapy (15%), radiation (19%), or a combination of radiation and chemotherapy (42%).
  • Statistically, stages greater than IE, presence of DLBCL, rapid clinical growth, abundant apoptosis, presence of vascular invasion, high mitotic rate, and infiltration of the perithyroidal soft tissue were significantly associated with death with disease.
  • In summary, PTLs typically occur in middle- to older-aged individuals as a thyroid mass, with a predilection for females.
  • Despite their histologic heterogeneity and frequent simulation of other lymphoma subtypes, virtually all PTLs are lymphomas of MALT-type arising in the setting of LT.
  • Mixed DLBCL and MZBL are common.
  • Overall, PTLs have a favorable outcome with appropriate therapy, but prognosis depends on both clinical stage and histology.
  • MZBL and stage IE tumors have an excellent prognosis, whereas tumors with a large cell component or DLBCL or stage greater than IE have the greatest potential for a poor outcome.
  • [MeSH-major] Lymphoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Follicular / pathology. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10800981.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Ohye H, Fukata S, Hirokawa M: [Malignant lymphoma of the thyroid]. Nihon Rinsho; 2007 Nov;65(11):2092-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma of the thyroid].
  • Primary malignant lymphoma of thyroid is frequently associated with Hashimoto's thyroiditis and it is usually non-Hodgkin type.
  • Thyroid lymphoma is common in women and the mean age at onset is 60 years old.
  • The majority of histopathologic types are extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, diffuse large B-cell lymphoma, and mixed type of above two.
  • If the findings on ultrasonography and fine needle aspiration cytology are suspected thyroid lymphoma, histopathological diagnosis of tissue obtaining from open biopsy is necessary.
  • The treatment for thyroid lymphoma consists of chemotherapy (CHOP), rituximab combined with CHOP, and radiation therapy.
  • It is selected based on the histopathologic type and the extent of disease.
  • The prognosis depends on the histopathologic type and the staging.
  • It should be recognized that early diagnosis and correct treatment lead to favorable prognosis.
  • [MeSH-major] Lymphoma, B-Cell. Lymphoma, Non-Hodgkin. Thyroid Neoplasms
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Female. Hashimoto Disease / complications. Humans. Middle Aged. Molecular Diagnostic Techniques. Neoplasm Staging. Prednisolone / administration & dosage. Prognosis. Radiotherapy. Rituximab. Ultrasonography. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018576.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 15
  •  go-up   go-down


25. Toubai T, Ota S, Onodera M, Baba U, Fujisawa F, Miura Y, Toyoshima N, Tanaka J, Asaka M, Imamura M: [Evaluation of bone marrow involvement by FDG-PET for refractory Hodgkin lymphoma treated by unrelated allogeneic bone marrow transplantation]. Rinsho Ketsueki; 2003 Jul;44(7):446-50
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of bone marrow involvement by FDG-PET for refractory Hodgkin lymphoma treated by unrelated allogeneic bone marrow transplantation].
  • A 23-year-old female patient was diagnosed as having Hodgkin lymphoma (mixed cellularity type, clinical stage III B) in September 2000.
  • She underwent ABVD chemotherapy and irradiation of a mediastinal lesion, resulting in complete remission.
  • However, the disease reoccurred three month after the completion of initial treatment.
  • She was admitted to our hospital for allogeneic stem cell transplantation.
  • She received re-induction chemotherapy but did not achieve complete remission.
  • Skin GVHD was detected at the same time and she was treated with steroid hormones, resulting in improvement.
  • FDG-PET is useful for the monitoring disease status and for determining the optimal timing of various treatments.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Tomography, Emission-Computed. Transplantation, Homologous

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12931562.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


26. Porcaro AB, D'Amico A, Novella G, Curti P, Ficarra V, Antoniolli SZ, Martignoni G, Matteo B, Malossini G: Primary lymphoma of the kidney. Report of a case and update of the literature. Arch Ital Urol Androl; 2002 Mar;74(1):44-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the kidney. Report of a case and update of the literature.
  • OBJECTIVES: To report on a case of primary renal lymphoma (PRL) and update the literature concerning this topic.
  • MATERIALS AND METHODS: A 48-year-old woman underwent surgery for the presumed diagnosis of renal cell carcinoma with bilateral adrenal metastases.
  • RESULTS: The neoplasm was assessed as primary renal non-Hodgkin high grade lymphoma, diffuse large B-cell type.
  • Unfortunately, 5 weeks later the patient was lost since missing chemotherapy and follow-up.
  • Several histogenetic theories of the disease have been postulated since the kidney does not normally contain lymphoid tissue.
  • Investigators reported many classes of non-Hodgkin lymphoma which include large, small, intermediate and mixed cell types with high, intermediate or low grade histologies.
  • The neoplastic lymphoid cells may express both B and T immunoblastic phenotypes, primary renal Hodgkin lymphoma has also been reported.
  • The disease may present with progressive renal failure of either oliguric or non oliguric type.
  • Imaging studies in diagnosing and staging primary renal lymphomas include ultrasound examination (US) and computed tomography (CT); there are also some reports of magnetic resonance imaging (MRI).
  • Up to now, there are no standard treatment modalities for this entity since the small number of cases reported.
  • Multidrug chemotherapy is mandatory for high grade lymphoma and when the disease is diagnosed preoperatively.
  • High dose chemotherapy in the future may offer a curative approach in primary bilateral renal disease and without end-stage renal disease.
  • Prognosis may be improved by early detection of disease and by performing systemic chemotherapy.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12053451.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Number-of-references] 33
  •  go-up   go-down


27. Alpen B, Kuse R, Parwaresch R, Müller-Hermelink HK, Stolte M, Neubauer A: Ongoing monoclonal B-cell proliferation is not common in gastric B-cell lymphoma after combined radiochemotherapy. J Clin Oncol; 2004 Aug 1;22(15):3039-45
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ongoing monoclonal B-cell proliferation is not common in gastric B-cell lymphoma after combined radiochemotherapy.
  • PURPOSE: Gastric marginal-zone B-cell lymphoma (MZBCL) of the mucosa-associated lymphoid tissue (MALT) is associated with chronic Helicobacter pylori gastritis.
  • Whether this is paralleled by cure of the lymphoma remains unclear.
  • Persisting monoclonal bands for immunoglobulin heavy chain variable region (VH) representing the lymphoma clone have been described in up to 50% of patients in CR.
  • PATIENTS AND METHODS: Biopsy samples of 20 patients receiving chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone and irradiation were analyzed before and after therapy.
  • Study patients had Ann Arbor stage I/II primary gastric cancer, including four cases of MZBCL of MALT type, 12 cases of diffuse large-cell lymphomas (DLCL), and four cases of mixed MALT type/DLCL.
  • PCR in this patient showed persistent B-cell clonality.
  • This may result in better elimination of residual lymphoma cells.
  • [MeSH-major] B-Lymphocytes / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Division. Clone Cells. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Gene Rearrangement, B-Lymphocyte. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans. Immunoglobulin Heavy Chains / genetics. Male. Middle Aged. Polymerase Chain Reaction. Prednisone / therapeutic use. Retrospective Studies. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Society of Clinical Onocology
  • (PMID = 15284253.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


28. Costello RT, Mallet F, Barbarat B, Schiano De Colella JM, Sainty D, Sweet RW, Truneh A, Olive D: Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity. Leukemia; 2003 Dec;17(12):2500-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity.
  • Stimulation by CD40 ligand (L) improves B-cell malignancy immunogenicity, and also induces proliferative signals.
  • To avoid these tumorigenic effects, we studied an alternate way of tumor-cell stimulation by homologous to lymphotoxin, inducible expression, competing for GpD of herpesvirus, which binds to the herpesvirus entry mediator (HVEM), and is expressed on T-lymphocytes (LIGHT), the ligand for HVEM, a new member of the tumor necrosis factor (TNF)/TNF-receptor (-R) family.
  • We focused our attention on mantle cell lymphoma, a subtype of B-cell malignancy of poor prognosis.
  • Triggering by LIGHT, in contrast to CD40L stimulation, did not increase lymphoma proliferation nor decrease chemotherapy entrance.
  • We observed an upregulation of the TNFR apoptosis-inducing ligand Fas, and in contrast to CD40L-induced protection, an enhancement of lymphoma sensitivity to Fas-induced apoptosis.
  • LIGHT triggering increased lymphoma cell recognition in a mixed lymphocyte response.
  • In conclusion, LIGHT-mediated triggering renders B-cell lymphomas more immunogenic and sensitive to apoptosis, without inducing proliferation.
  • [MeSH-major] Antigens, CD95 / metabolism. Apoptosis / genetics. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / therapy. Receptors, Tumor Necrosis Factor / genetics. Receptors, Virus / genetics
  • [MeSH-minor] Antigens, CD40 / metabolism. B-Lymphocytes / immunology. B-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / secretion. Cell Adhesion / immunology. Cell Death / immunology. Cell Division / immunology. Dendritic Cells / immunology. Dendritic Cells / metabolism. Gene Expression. Humans. Immunotherapy. Interleukin-2 / secretion. Ligands. Lymphocyte Culture Test, Mixed. Lymphoma, Mantle-Cell / immunology. Lymphoma, Mantle-Cell / therapy. Receptors, Tumor Necrosis Factor, Member 14. Transfection

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14562115.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Antigens, CD95; 0 / Interleukin-2; 0 / Ligands; 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Member 14; 0 / Receptors, Virus; 0 / TNFRSF14 protein, human
  •  go-up   go-down


29. Wajchman J, Simmons WJ, Klein A, Koneru M, Ponzio NM: Interleukin-12-induced cytotoxicity against syngeneic B cell lymphomas of SJL/J mice. Leuk Res; 2002 Jun;26(6):577-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-12-induced cytotoxicity against syngeneic B cell lymphomas of SJL/J mice.
  • The B cell lymphomas (RCS) that develop spontaneously in 90% of aging SJL/J mice stimulate syngeneic CD4+ Vbeta16+ Th2 cells to produce cytokines, such as IL-4 and IL-5, which promote lymphoma growth.
  • Antibody depletion studies revealed at least two types of RCS/IL-12-induced cytotoxic cells:.
  • Despite high titers of IFN-gamma in the SN of co-culture of SJL spleen and gamma-RCS cells, cytotoxicity only developed if IL-12 was also included in the co-cultures.
  • The results of RNAse protection assays and multi-parameter FACS analysis demonstrated an upregulation of IFN-gamma and decrease in IL-4 by activated Th cells in co-cultures with IL-12.
  • Results of in vivo experiments support this hypothesis, as judged by tumor growth assays and FACS analysis of the tumor cell content of lymphoid tissues.
  • Inhibition of lymphoma growth was observed in mice given gamma-RCS/IL-12-induced effector cells prior to injection of viable RCS cells.
  • These results demonstrate that IL-12 can be used to alter the host immune response leading to induction of cytotoxic effector cells that inhibit the development and/or progressive growth of otherwise resistant B cell lymphomas in SJL/J mice.
  • [MeSH-major] Interleukin-12 / immunology. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Animals. Immunotherapy, Adoptive / methods. Killer Cells, Natural / drug effects. Killer Cells, Natural / immunology. Lymphocyte Culture Test, Mixed. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Mice. Mice, Inbred Strains. Neoplasm Transplantation. T-Lymphocytes, Cytotoxic / drug effects. T-Lymphocytes, Cytotoxic / immunology. Transplantation, Isogeneic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12007506.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 187348-17-0 / Interleukin-12
  •  go-up   go-down


30. Fadoo Z, Belgaumi A, Alam M, Azam I, Naqvi A: Pediatric lymphoma: a 10-year experience at a tertiary care hospital in Pakistan. J Pediatr Hematol Oncol; 2010 Jan;32(1):e14-8
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric lymphoma: a 10-year experience at a tertiary care hospital in Pakistan.
  • SUMMARY: Lymphoma is the third most common childhood malignancy.
  • A retrospective study was carried out at Aga Khan University Hospital, Karachi on children (<15 y) diagnosed with lymphoma from 1998 to 2007.
  • Fifty-one children were diagnosed as non-Hodgkin lymphoma (NHL).
  • Most common histopathologic subtype of NHL was Burkitt lymphoma (55%).
  • Abdominal mass was the main presenting feature of Burkitt and diffuse large B cell lymphoma.
  • T-lymphoblastic lymphoma presented mainly as mediastinal mass.
  • Ten children died, 4 secondary to tumor lysis syndrome, 5 because of disease progression, and 1 with chemotherapy-induced toxicity.
  • One-third of the patients left without treatment.
  • Seventeen children were diagnosed as Hodgkin lymphoma with mixed cellularity as the commonest subtype (65%).
  • Overall survival of children with NHL and Hodgkin lymphoma was 62% and 94%, respectively.
  • [MeSH-major] Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20051771.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Parker JR, López-Terrada D, Gresik MV, Vogel H, Baumgartner JE, Finegold MJ: Neutrophil-rich anaplastic large cell lymphoma of the skull presenting after head trauma. Pediatr Dev Pathol; 2001 Jul-Aug;4(4):397-401
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophil-rich anaplastic large cell lymphoma of the skull presenting after head trauma.
  • The presentation of anaplastic large cell lymphoma in bone is uncommon.
  • We report a case of anaplastic large cell lymphoma of the skull that was diagnosed after head trauma.
  • Histopathologically, the initial evaluation suggested osteomyelitis because of a mixed inflammatory infiltrate with large numbers of neutrophils.
  • Fluorescence in situ hybridization (FISH) showed rearrangement of the ALK gene, which usually results from the t(2;5) translocation, present in most anaplastic large cell lymphomas.
  • The patient has tolerated chemotherapy and is free of disease 12 months later.
  • [MeSH-major] Antigens, CD30. Craniocerebral Trauma. Lymphoma, Large-Cell, Anaplastic / pathology. Neutrophils / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Activin Receptors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Nucleus / chemistry. Cell Nucleus / genetics. Cell Nucleus / pathology. Child. DNA, Neoplasm / analysis. E2F6 Transcription Factor. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Protein-Serine-Threonine Kinases / analysis. Protein-Serine-Threonine Kinases / genetics. Repressor Proteins / analysis. Transcription Factors / analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Head Injuries.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11441342.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / DNA, Neoplasm; 0 / E2F6 Transcription Factor; 0 / E2F6 protein, human; 0 / Repressor Proteins; 0 / Transcription Factors; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / Activin Receptors
  •  go-up   go-down


32. Singh A, Thapar V, Prabhu R, Naresh K, Joshi A, Supe A: Isolated splenic lymphoma: an elusive preoperative diagnosis. Indian J Gastroenterol; 2000 Oct-Dec;19(4):184-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic lymphoma: an elusive preoperative diagnosis.
  • Four patients underwent splenectomy for various clinical and radiological diagnoses and were found to have primary splenic lymphoma at surgery and histology.
  • The diagnosis was classical Hodgkin's lymphoma, mixed cellularity type (one case); marginal zone B-cell non-Hodgkin's lymphoma (one case); and large B cell type non-Hodgkin's lymphoma (two cases).
  • The first two patients had multiple nodules in the spleen measuring 0.1-0.5 cm while large cell lymphomas had large nodules (largest measuring 11 cm x 7 cm x 4 cm).
  • Mean follow up of these patients was 11 months; all patients received chemotherapy.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / surgery. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / surgery. Splenic Diseases / diagnosis. Splenic Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intraoperative Period. Male. Middle Aged. Preoperative Care. Splenectomy / methods. Splenectomy / mortality. Splenomegaly / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11059187.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] INDIA
  •  go-up   go-down


33. Zuckerman E, Zuckerman T: Hepatitis C and B-cell lymphoma: the hemato-hepatologist linkage. Blood Rev; 2002 Jun;16(2):119-25
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C and B-cell lymphoma: the hemato-hepatologist linkage.
  • Hepatitis C virus (HCV)-lymphotropism may be responsible for the development of mixed cryoglobulinemia (MC) and other lymphoproliferative disorders associated with HCV infection.
  • An association between HCV infection and B-cell lymphoma has been largely demonstrated in several geographical areas with prevalence ranging between 7.4 and 37%.
  • However, the intimate pathogenetic mechanism involved in HCV-associated lymphomas remains considerably unknown.
  • It is reasonable to assume that several different pathogenetic mechanisms operate in the wide spectrum of HCV-related lymphomas which includes the 'idiopathic', non-cryoglobulinemic, intermediate to high-grade lymphoma, and the more common indolent, low-grade lymphoma, preceded by long standing symptomatic MC type II.
  • In most cases, HCV has no significant impact on response to chemotherapy or survival of lymphoma patients.
  • Treatment with chemotherapy is relatively safe, and interruption of treatment regimens is usually not required.
  • Whether to treat low-grade HCV-related lymphomas with anti-viral therapy is still debatable, but encouraging data emerge from recent studies.
  • [MeSH-major] Hepatitis C / complications. Lymphoma, B-Cell / virology
  • [MeSH-minor] Gastroenterology. Hematology. Humans. Prevalence. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12127955.001).
  • [ISSN] 0268-960X
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 106
  •  go-up   go-down


34. Azim HA, Santoro L, Bociek RG, Gandini S, Malek RA, Azim HA Jr: High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis. Ann Oncol; 2010 May;21(5):1064-71
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis.
  • BACKGROUND: Aggressive non-Hodgkin's lymphoma (NHL) represents approximately 60% of lymphomas in the West and even more in the developing world. cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is recognized as the standard chemotherapy regimen and the addition of rituximab to B-cell subtypes has been shown to significantly improve treatment outcomes.
  • Thus, CHOP is still offered to these patients as well as those with T-cell subtypes.
  • METHODS: A Medline and Cochrane library search was carried out using the search terms 'CHOP', 'lymphoma' and 'randomized trials'.
  • Pooling of data was carried out using the mixed effect model.

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19850640.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


35. Liu C, DeNardo G, Tobin E, DeNardo S: Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells. Cancer Biother Radiopharm; 2004 Oct;19(5):545-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
  • AIM: Anti-HLA-DR and anti-CD20 monoclonal antibodies (MAbs) have been effective for immunotherapy and radioimmunotherapy in non-Hodgkin's lymphoma (NHL).
  • The aim of our study was to compare the antilymphoma effects of Lym-1 and rituximab in human lymphoma cell lines, using assays of viability, apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC), under conditions relevant to the clinic.
  • METHODS: To characterize response relationships at varied concentrations of Lym-1 and rituximab, growth inhibition and cell death were assayed over 96 hours in four NHL cell lines derived from Burkitt's or large-cell lymphoma patients.
  • Lym-1 had a substantial, and statistically greater, effect than rituximab over longer intervals of time.
  • Lym-1-induced apoptosis was greater than that of rituximab in all cell lines tested.
  • Lym-1, both the chimeric form and the mouse parent, mediate ADCC more effectively, in the presence of a total peripheral blood leukocyte (PBL) population, than does rituximab, although the results for CDC activity were mixed.
  • CONCLUSIONS: In conclusion, Lym-1 had more potent direct and indirect cytotoxic effects than rituximab in lymphoma cells under conditions achievable in patients.
  • Because the HLA-DR target antigen of Lym-1 is enriched on most B-cell lymphomas, these results support its complementary use in patients as an alternative to CD20 for monoimmunotherapy and for combination immunotherapy with rituximab, because the HLA-DR and CD20 antigens are physically and functionally coupled on human B cells.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Antineoplastic Agents / therapeutic use. HLA-DR Antigens / immunology. Immunotherapy / methods. Lymphoma / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Apoptosis. Blotting, Western. Burkitt Lymphoma / drug therapy. Caspase 3. Caspases / metabolism. Cell Line, Tumor. Cell Proliferation. Cell Survival. Complement System Proteins. Dose-Response Relationship, Drug. Enzyme Activation. Humans. Leukocytes / cytology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Poly(ADP-ribose) Polymerases / metabolism. Rituximab. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15650447.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 47829
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / HLA-DR Antigens; 0 / Lym-1 monoclonal antibody; 4F4X42SYQ6 / Rituximab; 9007-36-7 / Complement System Proteins; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


36. Brousse C, Baumelou E, Morel P: Primary lymphoma of bone: a prospective study of 28 cases. Joint Bone Spine; 2000;67(5):446-51
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of bone: a prospective study of 28 cases.
  • PURPOSE: To conduct a prospective study of primary lymphoma of bone (PLB) comparatively with extraskeletal non-Hodgkin's lymphomas (ESNHLs) and secondary lymphoma of bone (SLB).
  • PATIENTS AND METHODS: The 28 cases of PLB, 2932 cases of ESNHL, and 219 cases of SLB included between April 1, 1993, and October 1, 1997, in a treatment protocol for NHL developed by the Adult Lymphoma Study Group, were studied prospectively.
  • In the PLB group, 54% of patients had diffuse large cell tumors and 11% diffuse mixed tumors; in the ESNHL group, 39% had diffuse large cell, 13% diffuse mixed, and 8% diffuse immunoblastic tumors; and in the SLB group, 45% had diffuse large cell, 10% diffuse mixed, and 12% diffuse immunoblastic tumors.
  • A complete or partial response to induction therapy was noted in 86% of PLB patients, 84% of ESNHL patients, and 78% of SLB patients.
  • Further studies are needed to determine the effect of radiation therapy at completion of the treatment protocol and to look for prognostic factors associated with bone involvement.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prospective Studies. Surveys and Questionnaires. Survival Rate. Treatment Outcome. Vindesine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11143912.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; LNH 87 protocol
  •  go-up   go-down


37. Valli VE, Vernau W, de Lorimier LP, Graham PS, Moore PF: Canine indolent nodular lymphoma. Vet Pathol; 2006 May;43(3):241-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine indolent nodular lymphoma.
  • Dogs of 26 breeds, plus 13 of mixed breeding or unknown lineage, were represented.
  • B-Cell lymphomas (CD79a+) predominated.
  • Marginal zone lymphoma (MZL), the largest group, involved lymph node (33 cases) and spleen (13 cases), with both tissues involved in five of these cases.
  • Follicular lymphoma (FL) involved lymph nodes (five cases), and mantle cell lymphoma (MCL) occurred as solitary splenic masses (three cases).
  • Nodal CD3+ T-zone lymphomas (TZL) (10 cases), were included since they resembled late-stage MZL at the architectural level.
  • Clonality status was determined in 54 cases by analysis of immunoglobulin heavy chain (IGH) and T-cell antigen receptor gamma (TCRG) gene rearrangement.
  • Limited survival data obtained for 18 dogs indicated that the B-cell lymphomas (MZL, MCL, and FL) and the T-cell lymphoma (TZL) were associated with indolent behavior and long survival.
  • Although to the authors' knowledge, the true incidence of canine indolent lymphomas is unknown, the tumors are not rare and may have been underrecognized.
  • [MeSH-major] Dog Diseases / diagnosis. Lymphoma, Follicular / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Dogs. Female. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / pathology. Lymphoma, Mantle-Cell / veterinary. Male. Splenic Neoplasms / diagnosis. Splenic Neoplasms / drug therapy. Splenic Neoplasms / pathology. Splenic Neoplasms / veterinary

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16672571.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


38. Linch DC, Smith P, Hancock BW, Hoskin PJ, Cunningham DC, Newland AC, Milligan D, Stevenson PA, Wood JK, Maclennan KA, Vaughan B, Vaughan G, Gregory WM: A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol; 2000;11 Suppl 1:87-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma.
  • BACKGROUND: Between 1987 and 1991, the British National Lymphoma Investigation randomized 459 patients with non-Hodgkin's lymphoma with a large-cell component to either CHOP or the PACEBOM regimen.
  • PATIENTS AND METHODS: Four hundred fifty-nine eligible patients were included in this trial, four hundred one with diffuse large-cell lymphoma and fifty-eight with diffuse mixed-cell lymphoma according to the Working Formulation.

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10707786.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


39. Lorusso V, Palmieri G, Bianco AR, Abate G, Catalano G, De Vita F, Dammacco F, Lauta VM, Lucarelli G, Polimeno G, Mantovani G, D'Aprile M, Marzullo F, De Lena M: CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group. Int J Oncol; 2000 Jan;16(1):149-54
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
  • From January 1992 to December 1995, 129 patients with previously untreated non-Hodgkin's lymphoma were randomised in a phase III multicenter trial to receive CEOP-B/VIMB or ProMACE-CytaBOM.
  • Eligibility criteria included intermediate or high grade lymphoma (follicular large cell, diffuse small cleaved-cell, diffuse mixed, diffuse large-cell and immunoblastic) with an Ann Arbor stage II bulky, III or IV.
  • At a median follow-up of 60 months there were no significant differences between the treatment response rates [82% (60%CR) for CEOP-B/VIMB vs. 81% (69% CR) for ProMACE-CytaBOM].
  • Conversely, with regard to disease-free survival, a significant difference was observed between the two treatment arms (42% for CEOP-B/VIMB vs. 24% for ProMACE-CytaBOM at 5 years; p=0.046).
  • Moreover, when response rates and outcome were analysed for different prognostic subgroups according to International Prognostic Index, no significant differences were observed between the treatment groups.
  • It is important to note that neither regimen was able to improve outcome of poor risk patients who fared badly with both treatments (median survival 9 and 8 months respectively).
  • Toxicity was also similar in both treatments with grade 3-4 leukopenia observed in 39% and 47% of cases and grade 3-4 thrombocytopenia in 24% and 27% of cases respectively.
  • In conclusion, in this study CEOP-B/VIMB was not superior to ProMACE-CytaBOM in aggressive lymphomas and the alternating strategy failed to improve outcome of poor risk patients in which newer more aggressive treatments are needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10601560.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CEOP-B protocol; PROMACE-CytaBOM protocol
  •  go-up   go-down


40. Ogasawara T, Yasuyama M, Kawauchi K: [Biclonal light chain gammopathy in multiple myeloma--a case report]. Nihon Rinsho Meneki Gakkai Kaishi; 2002 Apr;25(2):170-6
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1990, she had a chemotherapy for diffuse mixed cell lymphoma.
  • She eventually developed angioimmunoblastic T-cell lymphoma.
  • Biclonal gammopathy associated with malignant lymphoma is rare in case of multiple myeloma and may provide some insight into the pathogenesis of plasma cell tumors.
  • [MeSH-minor] Aged. Female. Humans. Immunoglobulin kappa-Chains / analysis. Immunoglobulin lambda-Chains / analysis. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / immunology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12043184.001).
  • [ISSN] 0911-4300
  • [Journal-full-title] Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology
  • [ISO-abbreviation] Nihon Rinsho Meneki Gakkai Kaishi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains
  •  go-up   go-down


41. Kojima M, Nakamura S, Nishikawa M, Itoh H, Miyawaki S, Masawa N: Idiopathic multicentric Castleman's disease. A clinicopathologic and immunohistochemical study of five cases. Pathol Res Pract; 2005;201(4):325-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These include HIV infection, autoimmune-disease-associated lymphadenopathy, idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia, "idiopathic MCD", POEMS syndrome (polyneuropathy, anasarca, organomegaly, endocrinopathy, M-proteins, and skin lesions), and non-Hodgkin's lymphomas.
  • However, during the course of disease, minimal diagnostic criteria for POEMS syndrome, i.e., monoclonal plasma cell proliferation and sensory motor neuropathys, were absent in all five cases.
  • Histologically, three lesions exhibited a mixed type of Castleman's disease, and two exhibited the hyaline-vascular type.
  • The majority of the germinal centers were of the hyaline-vascular or epithelioid germinal type, with a few hyperplastic germinal centers.
  • Moderate to large sheets of plasma cells were observed in three mixed type cases.
  • [MeSH-minor] Aged. Biomarkers / metabolism. Diagnosis, Differential. Drug Therapy, Combination. Female. Humans. Hyperplasia. Immunoenzyme Techniques. Male. Middle Aged. POEMS Syndrome / diagnosis. Treatment Outcome

  • Genetic Alliance. consumer health - Castleman's Disease.
  • Genetic Alliance. consumer health - Multicentric Castleman's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991840.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


42. Koffi G, Kouakou B, Ndiaye FS, Ndathz E, Sanogo I, Sangare A: [Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience]. Bull Cancer; 2007 Oct;94(10):902-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience].
  • [Transliterated title] Caractéristiques thérapeutiques et évolutives des lymphomes folliculaires du Noir africain: expérience de la Côte d'Ivoire.
  • We reported in this study a treatment results about 36 Africans patients with follicular lymphoma.
  • The average age of patients was 18 to 73 years old with a median age at 50.83 years old and a sex ratio of 1.
  • Histological, we mainly notified follicular lymphoma constituted of small cells 50%, followed by mixed follicular and large cells lymphomas with respectively 27.78 and 22.22%.
  • Using varieties of therapeutics regiments, we obtained 41.67% of complete remission.
  • Indeed, the follicular lymphomas constituted by large cells and mixed cells had higher rate of complete remission with respectively 46.67% and 40% in relation with those of small cells with a higher failure rate.
  • After a long period, 25 cases of death have been reported, 5 cases of losing sight and 6 patients are still alive and following treatment.
  • The short survival delay time of our patients didn't permit time to observe transformation case in diffuse large cell lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Cote d'Ivoire. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964984.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CHOP-B protocol; COP protocol 2
  •  go-up   go-down


43. Babovic N, Jelic S, Jovanovic V: Primary non-Hodgkin lymphoma of the breast. Is it possible to avoid mastectomy? J Exp Clin Cancer Res; 2000 Jun;19(2):149-54
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin lymphoma of the breast. Is it possible to avoid mastectomy?
  • Primary lymphoma of the breast is a rare disease that has been estimated to represent from 0.05% to 0.53% of all malignant breast tumors and approximately 2.2% of all extranodal lymphomas.
  • The aim of this study is to review all cases of primary lymphoma of the breast at the Institute of Oncology and Radiology of Serbia from 1984 to 1996 in order to determine the incidence, patterns of clinical presentation, radiological features, histopathology, mode of therapy and outcome of the disease.
  • The clinical histories of ten patients with breast lymphomas were reviewed.
  • Ten cases of primary lymphoma of the breast have been identified during the 12-yr period, presenting 0.05% of all patients with malignant breast disease.
  • Mammography and breast echography were unable to bring a suspicion of lymphoma.
  • Histologically, 6 cases were diffuse large cell, 3 of which with features consistent with immunoblastic lymphoma; 2 were diffuse mixed cells and 2 had small lymphocytic morphology.
  • In 4 out of 5 patients, in the clinical stage corresponding to the "operable breast cancer" category, the ex tempore histological analysis could not differentiate lymphoma from cancer, so that all of them had mastectomy with axillary dissection.
  • Further treatment included chemotherapy for 8 patients.
  • The rarity of this disease, and uneven treatment modalities make prognosis of breast lymphoma difficult.
  • With the limitations of available diagnostic procedures, it appears that most patients with breast lymphoma, in the stage corresponding to the "operable breast cancer" category, will unnecessarily undergo mastectomy and axillary dissection as primary treatment approach.
  • [MeSH-major] Breast Neoplasms / surgery. Lymphoma, Non-Hodgkin / surgery. Mastectomy, Radical
  • [MeSH-minor] Aged. Biopsy, Needle. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Incidence. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10965810.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ITALY
  •  go-up   go-down


44. Jackson CC, Medeiros LJ, Miranda RN: 8p11 myeloproliferative syndrome: a review. Hum Pathol; 2010 Apr;41(4):461-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This neoplasm affects patients of all ages, with a slight male predominance.
  • Lymph node biopsy in these patients has commonly shown lymphoblastic leukemia/lymphoma, most often reported as being of T-cell lineage, but bilineal myeloid/T-cell lymphomas and less often a myeloid sarcoma are also reported.
  • The natural history of this neoplasm is to evolve into acute leukemia, usually of myeloid or mixed lineage, and less frequently of T- or B-lymphoid lineage.
  • The prognosis is poor despite aggressive chemotherapy, with a few patients achieving long clinical remission after stem cell transplantation.
  • [MeSH-minor] Diagnosis, Differential. Humans. Receptor, Fibroblast Growth Factor, Type 1 / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc.
  • (PMID = 20226962.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1
  • [Number-of-references] 81
  •  go-up   go-down


45. Diop S, Deme A, Dangou JM, Ndiaye FS, Toure AO, Thiam D, Diop TM, Toure P, Diakhate L: [Non-Hodgkin's lymphoma in Dakar: study of 107 cases diagnosed between 1986 and 1998]. Bull Soc Pathol Exot; 2004 May;97(2):109-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's lymphoma in Dakar: study of 107 cases diagnosed between 1986 and 1998].
  • Non-Hodgkin's Lymphomas (NHL) are the most prevalent malignant hemopathies in Senegal.
  • Large cell lymphomas were predominant (67.2%), followed by small lymphocyte lymphomas (24.2%) and follicular lymphoma with 8.4% of cases.
  • Localization of lymphomas was exclusively nodal (30.8%) or extra nodal (31.7%) or mixed (37.3%).
  • Chemotherapy was used in 54 patients (78.2% of treated patients), surgery was performed in 6 patients (8.6%), association of radiotherapy and chemotherapy in 5 patients (7.2%) and 4 patients (5.7%) were treated with surgery + chemotherapy.
  • The average survival time was 344 days.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Urban Health / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. HIV Infections / complications. HIV Infections / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Population Surveillance. Prevalence. Prognosis. Risk Factors. Senegal / epidemiology. Sex Distribution. Survival Rate. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15255352.001).
  • [ISSN] 0037-9085
  • [Journal-full-title] Bulletin de la Société de pathologie exotique (1990)
  • [ISO-abbreviation] Bull Soc Pathol Exot
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down






Advertisement